/
INCY
$113.36-$1.30 (-1.13%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$22.7B
200M shares
52-week range
$66.83 – $115.56
95% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$29.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.88B | $2.16B | $2.67B | $2.99B | $3.39B | $3.70B | $4.24B | $5.14B |
| Cost of revenue | $94.1M | $114.2M | $131.3M | $151.0M | $207.0M | $255.0M | $312.1M | $372.1M |
| Gross profit | $1.79B | $2.04B | $2.54B | $2.84B | $3.19B | $3.44B | $3.93B | $4.77B |
| Gross margin | 95.0% | 94.7% | 95.1% | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% |
| R&D | $1.20B | $1.15B | $2.22B | $1.46B | $1.59B | $1.63B | $2.61B | $2.05B |
| Operating income | $129.2M | $402.0M | −$263.7M | $585.8M | $591.6M | $655.4M | $101.3M | $1.34B |
| EBITDA | $171.9M | $543.2M | −$178.2M | $630.2M | $599.6M | $919.4M | $408.2M | $1.76B |
| Net income | $109.5M | $446.9M | −$295.7M | $948.6M | $340.7M | $597.6M | $32.6M | $1.29B |
| Net margin | 5.8% | 20.7% | -11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
| EPS (diluted) | 0.51 | 2.05 | -1.36 | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5.6B | $7.58 | $6.79–$7.98 | 12 |
| 2027 | $6.2B | $8.91 | $8.14–$10.13 | 13 |
| 2028 | $6.5B | $9.47 | $7.65–$11.77 | 9 |
| 2029 | $4.6B | $3.71 | $3.55–$3.99 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$124.53
Price
$113.36
Implied upside
+10%
Peer comparison
Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
www.incyte.com- Employees
- 2,844
- IPO / List date
- Nov 3, 1993
- HQ
- WILMINGTON, DE
Held by traders on TradeandTell
No one on the platform currently holds INCY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 3,651,532 | $343.7M |
| Bridgewater Associatesas of 2026-03-31 | 130,296 | $12.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded INCY yet.
